Clearity

📍 San Diego, United States🗓 Founded 2008👥 26 employees💰 Last funded Jul 2008
The Clearity Foundation was launched in 2008 to help ovarian cancer patients and their physicians make better-informed treatment decisions, based on molecular profiling of tumors. The Clearity team includes scientists, physicians, and volunteers who feel passionately that the paradigm for ovarian cancer treatment needs to change from a trial-and-error approach to one that that individualizes therapy selection based on each patient’s tumor molecular profile. What We Do The Clearity Foundation is a 501(c)(3) not-for-profit organization that provides patient support services including lab test coordination, tumor blueprint interpretation, and clinical trial identification free of charge. Our services and educational programs are focused on: Assisting patients and physicians prioritize therapy options for recurrent and refractory ovarian cancer by providing information about the tumor molecular profile; Helping patients find clinical trials for which they may be eligible, based on the molecular characteristics of their tumor; Educating patients and physicians about the value of molecular profiling in ovarian cancer diagnosis and treatment; and Expediting the clinical development of novel targeted agents for ovarian cancer by creating a database that correlates tumor molecular profiles with treatment outcomes.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2008
Founded
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Clearity?
Clearity has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Clearity last raise funding?
The most recent investment in Clearity recorded on gritt.io was in July 2008.
When was Clearity founded?
Clearity was founded in 2008.
What industry is Clearity in?
Clearity operates in Hospitals and Health Care. Find similar Hospitals and Health Care investors on gritt.io.
Where is Clearity based?
Clearity is headquartered in San Diego, United States.